The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An APP-led intake model to expedite diagnostic workup for patients with suspected lymphoma.
 
Erin Taylor
No Relationships to Disclose
 
Jason Westin
Consulting or Advisory Role - Abbvie; Abbvie; ADC Therapeutics; Allogene Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Chugai Pharma; Genentech/Roche; Genmab; Janssen Scientific Affairs; Kite/Gilead; Lyell Immunopharma; Merck; MorphoSys/Incyte; Novartis; Nurix; Regeneron; Seagen
Research Funding - ADC Therapeutics; Allogene Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis; Nurix
 
Sairah Ahmed
No Relationships to Disclose
 
Ayushi Chauhan
No Relationships to Disclose
 
Dai Chihara
Honoraria - AstraZeneca/Daiichi Sankyo
Consulting or Advisory Role - ADC Therapeutics; Genmab; Regeneron
Research Funding - Bristol-Myers Squibb/Celgene; Genentech (Inst); Genmab (Inst); Ono Pharmaceutical (Inst)
 
Luis Fayad
No Relationships to Disclose
 
Fateeha Furqan
No Relationships to Disclose
 
Fredrick Hagemeister
No Relationships to Disclose
 
Hun Lee
Honoraria - Cancer Experts Now; DAVA Pharmaceuticals; Pfizer
Research Funding - AstraZeneca; BMS; Celgene; Merck; Oncternal Therapeutics; Seagen; Takeda
 
Swaminathan Iyer
Honoraria - Seagen
Consulting or Advisory Role - Acrotech Biopharma; DAAN Biotherapeutics; Legend Biotech; March Biosciences; Merck (Inst); Pfizer; Seagen; Secura Bio; Yingli Pharma
Speakers' Bureau - Targeted Oncology
Research Funding - Affimed Therapeutics (Inst); crispr therapeutics (Inst); Innate Pharma; Legend Biotech ; Merck; Rhizen Pharmaceuticals (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda; YingLing Pharma; YingLing Pharma; YingLing Pharma; YingLing Pharma; YingLing Pharma
 
Preetesh Jain
No Relationships to Disclose
 
Anath Lionel
No Relationships to Disclose
 
Chijioke Nze
No Relationships to Disclose
 
Maria Rodriguez
No Relationships to Disclose
 
Paolo Strati
No Relationships to Disclose
 
Karen Stolar
No Relationships to Disclose
 
Felicia Diaz
No Relationships to Disclose
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Ranjit Nair
No Relationships to Disclose